Last reviewed · How we verify
NCT06798207
A Phase 2 Clinical Trial of TQB2102 for Injection in the Treatment of Patients With Recurrent/Metastatic Advanced Gynecological Tumors to Evaluate the Safety and Efficacy
Phase 2 trial testing TQB2102 for injection in Gynecological Tumors in 170 participants. Currently enrolling.
1 May 2026
Quick facts
| Lead sponsor | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 170 |
| Start date | 13 March 2025 |
| Primary completion | 1 May 2026 |
| Estimated completion | 1 November 2026 |
| Sites | 31 locations across China |
Drugs / interventions tested
- TQB2102 for injection — full drug profile →
Conditions studied
- Gynecological Tumors — all drugs for Gynecological Tumors →
Sponsor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. — full company profile →
Who can join
18 and older, female only, with Gynecological Tumors. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Overall response rate (ORR)
Time frame: Baseline up to 12 months
ORR defined as percentage of participants achieving complete response (CR) and partial response (PR)
Sponsor's own description
TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against Human Epidermal Growth Factor Receptor 2 (HER2), a enzyme-cleavable linker, and a topoisomerase I inhibitor payload, which combine the ability of antibodies to specifically target tumour cells with the highly potent killing activity of drugs with payloads too toxic for systemic administration. This is a Phase 2 study to evaluate the efficacy,and safety of TQB2102 for injection in recurrent/metastatic advanced gynecological tumors.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies.
Zhou K, Liu X, Zhu H. · · 2025 · cited 2× · PMID 41185045 · DOI 10.1186/s13045-025-01752-9
Verify or expand the search:
- PubMed search for NCT06798207
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gynecological Tumors
Currently open trials in the same condition.
- NCT06191900 — Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors (advanced Cervical Cancer) · NA · recruiting
- NCT06145802 — Clinical Study of Autologous Tumor Infiltrating Lymphocyte Injection (GT316) in the Treatment of Advanced Solid Tumors ( · NA · recruiting
Other Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. trials
Trials by the same sponsor.
- NCT07052097 — Clinical Trial of TQC2938 Injection in Patients With Seasonal Allergic Rhinitis · Phase 2 · completed
- NCT06929195 — Clinical Trial to Evaluate the Tolerance of TQB2210 Injection · Phase 1 · completed
- NCT06542614 — Treatment of Moderate to Severe Plaque Psoriasis · Phase 2 · completed
- NCT06451640 — A Extension Clinical Study of TQC2731 Injection in the Treatment of Chronic Sinusitis With Nasal Polyps · Phase 2 · completed
- NCT06438783 — TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors · Phase 1 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06798207 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Last refreshed: 16 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06798207.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing